secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0000950170-22-014263
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q2 rev $26.8M, net loss $66.6M; ARC-8 PDAC data similar to historical chemo benchmarks; cash $1.27B
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.
- Collaboration revenue $26.8M for Q2 2022 vs $9.5M YoY; net loss $66.6M vs $76.0M YoY.
- ARC-8 interim analysis for quemliclustat in PDAC: data from randomized cohort similar to historical chemo benchmarks; Arcus and Gilead await mature data in 2023.
- Four registrational Phase 3 trials of domvanalimab-based combinations ongoing or planned; ARC-7 topline disclosure expected H2 2022.
- AB521 (HIF-2a inhibitor) Phase 1/1b to start Q3 2022; AB801 (AXL inhibitor) nominated; two new molecules expected in clinic in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/0000950170-22-014263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022014263/rcus-20220803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer